Results 121 to 130 of about 2,650 (185)

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration. [PDF]

Eye (Lond)
Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, Lawrence D, Holz FG.   +6 more
europepmc   +1 more source

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series [PDF]

Eandi, Chiara
core   +1 more source

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype. [PDF]

Sci Rep
Fukuda Y, Sakurada Y, Kotoda Y, Kikushima W, Kashiwagi K.   +4 more
europepmc   +1 more source

Increased aqueous flare after intravitreal brolucizumab injections compared to aflibercept in neovascular age-related macular degeneration. [PDF]

Graefes Arch Clin Exp Ophthalmol
Hashimoto Y, Arai Y, Takahashi H, Tampo H, Kondo R, Takahashi H, Yoshida H, Takahashi R, Inoda S, Kaburaki T, Yanagi Y.   +10 more
europepmc   +1 more source

Choroidal Thickness and brolucizumab intravitreal injection: Cause or effect of intraocular inflammation? [PDF]

Cennamo, Gilda, Costagliola, Ciro, Malvone, Emanuele, Rinaldi, Michele   +3 more
core   +1 more source

Evolution of Anti-Vascular Endothelial Growth Factor Clinical Trial Design for Treating Neovascular Age-Related Macular Degeneration. [PDF]

J Vitreoretin Dis
Klufas MA, Regillo CD, Mandava NK, Miller EG.   +3 more
europepmc   +1 more source

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen. [PDF]

Sci Rep
Kikushima W, Sakurada Y, Fukuda Y, Yoneyama S, Kotoda Y, Tsuru DV, Kashiwagi K.   +6 more
europepmc   +1 more source

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid. [PDF]

Eur J Ophthalmol
García-Serrano Fuertes R, Romero Martínez A, Suarez Pérez J, López Herrero F, Cabanás Jiménez M, Flores Córdoba A, Sánchez Vicente JL.   +6 more
europepmc   +1 more source

Outcomes of Re-Switching Anti-Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration. [PDF]

Korean J Ophthalmol
Suh YK, Lee SH, Kim MS.
europepmc   +1 more source

Predictive value of uninterrupted dry macula duration for discontinuation of anti-VEGF therapy in diabetic macular edema. [PDF]

Sci Rep
Murata T, Hirano T, Ideta S, Tanaka K, Shimura M.   +4 more
europepmc   +1 more source